Literature DB >> 22467549

Risk factors and outcomes of failed endoscopic retrograde cholangiopancreatography in liver transplant recipients with anastomotic biliary strictures: a case-control study.

Domingo Balderramo1, Oriol Sendino, Marta Burrel, Maria Isabel Real, Annabel Blasi, Graciela Martinez-Palli, Josep M Bordas, Juan Carlos Garcia-Valdecasas, Antoni Rimola, Miguel Navasa, Josep Llach, Andres Cardenas.   

Abstract

Anastomotic strictures (ASs) of the biliary duct after liver transplantation (LT) are primarily managed with endoscopic retrograde cholangiopancreatography (ERCP), but in some cases, this fails because of difficulties in passing the strictures. The aim of this case-control study was to examine specific risk factors for initial ERCP failure and the outcomes of percutaneous transhepatic cholangiography (PTC) as a second-line approach in LT recipients with ASs. Between January 2002 and December 2010, we identified LT recipients with ASs who experienced initial ERCP failure (which was defined as the inability to traverse the AS with guidewires in 2 or more consecutive procedures). A period-matched control group (ratio = 1:2) with ASs and initial ERCP success was analyzed. Preoperative, intraoperative, postoperative, and endoscopic variables were evaluated as risk factors. The outcomes of PTC and the need for hepaticojejunostomy (HJ) or retransplantation were evaluated. Seventeen cases who experienced initial ERCP failure were compared with 34 controls. The median times from LT to ERCP were similar (8.7 months for cases and 8.6 months for controls, P = not significant). A multivariate analysis revealed that previous bile leaks [odds ratio (OR) = 6.07, 95% confidence interval (CI) = 1.0-36.5] and more than 4 U of intraoperatively transfused red blood cells (OR = 11.51, 95% CI = 1.9-71.2) were independent risk factors for failure. PTC was an effective second-line treatment in only 3 of 12 cases (25%). The need for HJ was more frequent for the cases (13/17 or 76.5%) versus the controls (7/34 or 20.6%, P < 0.001). One patient in each group underwent retransplantation (P = not significant). In conclusion, previous bile leaks and high packed red blood cell transfusion requirements during surgery are risk factors for initial ERCP failure in LT recipients with ASs. A high proportion of these patients will need surgery as their final therapy.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2012        PMID: 22467549     DOI: 10.1002/lt.23371

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  4 in total

1.  Post-Transplantation Cytomegalovirus Infection Interplays With the Development of Anastomotic Biliary Strictures After Liver Transplantation.

Authors:  Pauline Georges; Clémentine Clerc; Célia Turco; Vincent Di Martino; Brice Paquette; Anne Minello; Paul Calame; Joséphine Magnin; Lucine Vuitton; Delphine Weil-Verhoeven; Zaher Lakkis; Claire Vanlemmens; Marianne Latournerie; Bruno Heyd; Alexandre Doussot
Journal:  Transpl Int       Date:  2022-06-02       Impact factor: 3.842

2.  Endoscopic management of bile leaks after liver transplantation: An analysis of two high-volume transplant centers.

Authors:  Oriol Sendino; Alejandro Fernández-Simon; Ryan Law; Barham Abu Dayyeh; Michael Leise; Karina Chavez-Rivera; Henry Cordova; Jordi Colmenero; Gonzalo Crespo; Cristina Rodriguez de Miguel; Constantino Fondevila; Josep Llach; Miquel Navasa; Todd Baron; Andrés Cárdenas
Journal:  United European Gastroenterol J       Date:  2017-05-25       Impact factor: 4.623

3.  Long-term results after adult ex situ split liver transplantation since its introduction in 1987.

Authors:  Harald Schrem; Moritz Kleine; Tim Oliver Lankisch; Alexander Kaltenborn; Lampros Kousoulas; Lea Zachau; Frank Lehner; Jürgen Klempnauer
Journal:  World J Surg       Date:  2014-07       Impact factor: 3.352

4.  ERCP-related complication is not the only cause of GI bleeding in post-liver transplantation patients: A case report.

Authors:  Zhen Ding; Xue-Lian Tang; Rong Lin; Chaoqun Han; Jun Liu
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.